JP2014515740A5 - - Google Patents

Info

Publication number

JP2014515740A5

JP2014515740A5 JP2014501575A JP2014501575A JP2014515740A5 JP 2014515740 A5 JP2014515740 A5 JP 2014515740A5 JP 2014501575 A JP2014501575 A JP 2014501575A JP 2014501575 A JP2014501575 A JP 2014501575A JP 2014515740 A5 JP2014515740 A5 JP 2014515740A5

Authority

JP

Japan

Prior art keywords

seq

chain variable

variable domain

antibody molecule

dabigatran

Prior art date

2012-03-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 229960003850 dabigatran Drugs 0.000 claims 28
• YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims 28
• 229930182480 glucuronide Natural products 0.000 claims 10
• 230000000694 effects Effects 0.000 claims 5
• 238000000034 method Methods 0.000 claims 5
• 230000035602 clotting Effects 0.000 claims 4
• 229960000288 dabigatran etexilate Drugs 0.000 claims 4
• KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 claims 4
• 229940002612 prodrug Drugs 0.000 claims 4
• 239000000651 prodrug Substances 0.000 claims 4
• 150000003839 salts Chemical class 0.000 claims 4
• 208000032843 Hemorrhage Diseases 0.000 claims 3
• 238000003556 assay Methods 0.000 claims 3
• 208000034158 bleeding Diseases 0.000 claims 3
• 230000000740 bleeding effect Effects 0.000 claims 3
• 230000003472 neutralizing effect Effects 0.000 claims 3
• 206010053567 Coagulopathies Diseases 0.000 claims 2
• 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 2
• 230000023555 blood coagulation Effects 0.000 claims 2
• 230000015271 coagulation Effects 0.000 claims 2
• 238000005345 coagulation Methods 0.000 claims 2
• 239000012634 fragment Substances 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
• 108090000190 Thrombin Proteins 0.000 claims 1
• 230000002429 anti-coagulating effect Effects 0.000 claims 1
• 239000003146 anticoagulant agent Substances 0.000 claims 1
• 229940127219 anticoagulant drug Drugs 0.000 claims 1
• 230000010100 anticoagulation Effects 0.000 claims 1
• 230000015556 catabolic process Effects 0.000 claims 1
• 238000004113 cell culture Methods 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 238000006731 degradation reaction Methods 0.000 claims 1
• 230000006866 deterioration Effects 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 230000004064 dysfunction Effects 0.000 claims 1
• 150000008134 glucuronides Chemical class 0.000 claims 1
• 230000000004 hemodynamic effect Effects 0.000 claims 1
• 208000014674 injury Diseases 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 238000012544 monitoring process Methods 0.000 claims 1
• 102000039446 nucleic acids Human genes 0.000 claims 1
• 108020004707 nucleic acids Proteins 0.000 claims 1
• 150000007523 nucleic acids Chemical class 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 229960004072 thrombin Drugs 0.000 claims 1
• 230000008733 trauma Effects 0.000 claims 1